Skip to main content
EMMA
OTC Life Sciences

Emmaus Life Sciences Flags Going Concern Doubt, Material Weaknesses in Q2 10-Q

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.012
Mkt Cap
$807.165K
52W Low
$0.007
52W High
$0.047
52W Position info
62% above low
Off High info
76% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

EMMA sits 62% above its 52-week low of $0.007.

Summary

Emmaus Life Sciences' Q2 10-Q reveals a going concern warning, a $60.1 million working capital deficit, and persistent material weaknesses in internal controls.


Key Events · Earnings and Guidance · EMMA

  • Going Concern Warning

    Management states there is substantial doubt about the company's ability to continue as a going concern for 12 months from the issuance date due to insufficient cash and uncommitted financing plans.

  • Liquidity Crisis

    Cash of $2.8 million and a working capital deficit of $60.1 million as of June 30, 2026. The company has no arrangements for restructuring or refinancing its debt.

  • Material Weaknesses Persist

    Disclosure controls and procedures were not effective as of June 30, 2026, due to ongoing material weaknesses including inadequate staffing and documentation in the finance department.

  • NIT License Revenue

    The NeoImmuneTech license agreement became effective May 15, 2026, contributing $4.8 million in upfront fee and royalty revenue for the quarter, but this does not resolve the liquidity shortfall.


Analysis · EMMA · Life Sciences

The company's own auditors state there is substantial doubt about its ability to continue as a going concern for the next 12 months. With only $2.8 million in cash, a $60.1 million working capital deficit, and no committed financing, the company may be unable to meet its obligations. The filing also confirms material weaknesses in internal controls remain, adding governance risk. The NIT licensing deal provides some revenue but does not resolve the liquidity crisis.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EMMA was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $807.2K. The 52-week trading range was $0.01 to $0.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EMMA - Latest Insights

EMMA
Nov 18, 2026, 8:13 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.023
Real-time Price: $0.023 info
Change: $0 (0%) info
Market Cap: $1.614M info
EMMA
Nov 18, 2026, 6:55 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.023
Real-time Price: $0.023 info
Change: $0 (0%) info
Market Cap: $1.614M info
EMMA
Sep 02, 2026, 3:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $0.06845
Real-time Price: $0.023 info
Change: -$0.04545 (-66%) info
Market Cap: $1.614M info
EMMA
Aug 14, 2026, 4:11 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.0115
Real-time Price: $0.023 info
Change: +$0.0115 (+100%) info
Market Cap: $1.614M info
EMMA
Aug 14, 2026, 3:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0115
Real-time Price: $0.023 info
Change: +$0.0115 (+100%) info
Market Cap: $1.614M info